INDICATIONS     CONTRA-INDICATIONS     DOSAGE     SIDE-EFFECTS     PREGNANCY     OVERDOSE     IDENTIFICATION     PATIENT INFORMATION

Logo ULCIM INJECTION

SCHEDULING STATUS:
S3

PROPRIETARY NAME
(and dosage form):

ULCIM INJECTION

COMPOSITION:
Each 2 mL contains 200 mg
cimetidine as hydrochloride.

PHARMACOLOGICAL CLASSIFICATION:
A 11.4.3 Medicines acting on gastro-intestinal tract: Other.

PHARMACOLOGICAL ACTION:
Cimetidine is a selective dose-dependent reversible histamine H2 - receptor antagonist. It's main action is to inhibit gastric acid secretion. It also inhibits competitively the other actions of histamine mediated by H2 - receptors. The decrease in gastric acid secretion occurs regardless of the nature of the physiological stimulus to secretion, i.e. basal (fasting) and nocturnal acid secretion, is reduced. Both the volume of secretion and the concentration of acid and pepsin in the secretion are reduced. It also inhibits gastric secretion elicited by muscarinic agonists or by gastrin.

INDICATIONS:
The treatment of gastric and duodenal ulcers, oesophageal reflux, Zollinger-Ellison syndrome and in other conditions associated with gastric hypersecretory states. ULCIM INJECTION is indicated in the management of those patients who are at high risk from haemorrhage of the upper gastro-intestinal tract due to hepatic failure and treatment with immuno-suppressive agents, following kidney transplant.

CONTRA-INDICATIONS:
Hypersensitivity to cimetidine. The safety in pregnancy and lactation has not been established.

WARNINGS:
Before giving cimetidine to patients with gastric ulcers the possibility of malignancy should be excluded since cimetidine may mask symptoms and delay diagnosis.

DOSAGE AND DIRECTIONS FOR USE:
Doses are expressed in terms of the base.
Cimetidine may be given by the intravenous or intramuscular routes; the total daily dose by any route should not normally exceed 2,4 g.
The usual dose of cimetidine by intravenous injection is 200 mg, which should be given slowly over at least 2 minutes and may be repeated every 4 to 6 hours. If a larger dose is required, or if the patient has cardiovascular impairment, intravenous infusion is recommended. For an intermittent intravenous infusion, the recommended dose is 400 mg (in 100 mL of sodium chloride 0,9% ), given over 30 minutes to 1 hour and repeated every 4 to 6 hours if necessary.
For a continuous intravenous infusion, the recommended rate is 50 mg to 100 mg per hour. The usual intramuscular dose is 200 mg which may be repeated at intervals of 4 to 6 hours.
The dosage of cimetidine should be reduced in patients with impaired renal function; suggested doses according to creatinine clearance are: creatinine clearance of 0 to 15 mL per minute, 200 mg twice daily; creatinine clearance of 15 mL to 30 mL per minute, 200 mg three times daily; creatinine clearance of 30 mL to 50 mL per minute, 200 mg four times daily; creatinine clearance of over 50 mL per minute, normal dosage.

Children:
Clinical experience in children is limited. Therefore, ULCIM INJECTION therapy cannot be recommended in children unless in the judgement of the physician, anticipated benefits outweigh the potential risk. In limited experience, 20 to 40 mg/kg per day has been administered in divided doses orally or parenterally. There is no evidence of clinical use in babies and ULCIM INJECTION should therefore not be given to infants under one year of age.

SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
The MOST common side-effects reported have been diarrhoea, dizziness, tiredness, headache and rashes.
Reversible confusional states, especially in the elderly or in seriously ill patients such as those with renal failure, have occasionally occurred. Cimetidine has a weak anti-androgenic effect and gynaecomastia and impotence have also occasionally occurred in men, receiving relatively high doses for conditions such as the Zollinger-Ellison syndrome.
Other adverse effects which have been reported are hypersensitivity reactions and fever, arthralgia and myalgia, blood disorders including agranulocytosis or neutropenia and thrombocytopenia, interstitial nephritis, headache, hepatotoxicity and cardiovascular disorders. Intravenous injections of cimetidine should be given slowly and intravenous infusion is recommended in patients with cardiovascular impairment.
It should be given in reduced dosage to patients with impaired renal function. Cimetidine crosses the placental barrier and is excreted into breastmilk. Reduction in the dosage of some agents, such as cyclosporin, lignocaine, nifedipine, phenytoin, suxamethonium, theophylline and warfarin may be needed.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
See "Side-effects and Special precautions" above. Treatment is supportive and symptomatic. Dialysis may be necessary in cases where renal failure is present.

IDENTIFICATION:
A clear, colourless solution in 2 mL clear, colourless ampoules.

PRESENTATION:
2 mL clear, colourless ampoules in packs of 10.

STORAGE INSTRUCTIONS:
Store below 25°C. Protect from light.
KEEP OUT OF REACH OF CHILDREN.

REGISTRATION NUMBER:
30/11.4.3/0492

NAME AND BUSINESS ADDRESS OF THE APPLICANT:
Quatromed Limited
10 Lindley Street
BETHLEHEM
9700

DATE OF PUBLICATION OF THIS PACKAGE INSERT:
November 1996

        PUL 01028/08/98

Updated on this site: May 2000

SAEPI HOME PAGE      TRADE NAME INDEX      GENERIC NAME INDEX      FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2000